Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab-first versus fecal microbiota transplantation-first strategy for multiple recurrent Clostridioides difficile infection
2021-004924-14Phase 4Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of bezlotoxumab and fidaxomicin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Global cure of the treatment strategy. Started Nov 2021; status: terminated.
02
Drugs
bezlotoxumabfidaxomicin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2021-004924-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004924-14.